Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Net revenue:
Total net revenue		$ 429,909	$ 396,289	$ 382,928
Cost of revenue:
Total cost of revenue	[1]	269,954	236,782	233,207
Gross profit		159,955	159,507	149,721
Operating expenses:
Research and development	[2]	57,752	52,729	49,784
Selling and marketing		49,664	42,820	47,254
General and administrative		44,391	41,723	40,144
Total operating expenses		151,807	137,272	137,182
Income from operations		8,148	22,235	12,539
Income (loss) on equity method investment		241	872	(149)
Other expense, net		(10,391)	(27,666)	(6,700)
Income (loss) before provision for income taxes		(2,002)	(4,559)	5,690
Provision for income taxes		3,345	1,752	1,863
Net income (loss)		$ (5,347)	$ (6,311)	$ 3,827
Net income (loss) per share - basic		$ (0.06)	$ (0.07)	$ 0.04
Net income (loss) per share - diluted		$ (0.06)	$ (0.07)	$ 0.04
Weighted average common shares used in computing net income (loss) per share:
Basic		92,095	92,031	89,874
Diluted		92,095	92,031	90,623
Net income		$ (5,347)	$ (6,311)	$ 3,827
Foreign currency translation adjustment		(3,998)	1,705	(238)
Change in defined benefit pension obligation		4,311	872	(236)
Comprehensive income (loss)		(5,034)	(3,734)	3,353
Products
Net revenue:
Total net revenue	[3]	214,715	176,647	167,302
Cost of revenue:
Total cost of revenue		127,287	102,100	95,882
Services
Net revenue:
Total net revenue	[4]	215,194	219,642	215,626
Cost of revenue:
Total cost of revenue		$ 142,667	$ 134,682	$ 137,325

[1] Includes cost of revenue from sales to the China joint venture, an equity method investment of $35,237 for the year ended June 30, 2022, $13,310 for the year ended June 30, 2021 and $13,174 for the year ended June 30, 2020, respectively. See Note 13.

[2] Includes chargeback to the China joint venture, an equity method investment related to research and development project of $2,336 and $430 for the year ending June 30, 2022 and June 30, 2021, respectively

[3] Includes sales to the China joint venture, an equity method investment of $45,545 for the year ended June 30, 2022, $12,033 for the year ended June 30, 2021 and $11,202 for the year ended June 30, 2020, respectively. See Note 13.

[4] Includes sales to the China joint venture, an equity method investment of $10,332 for the year ended June 30, 2022, $12,360 for the year ended June 30, 2021 and $7,851 for the year ended June 30, 2020, respectively. See Note 13.